87. Pulmonary veno-occlusive disease Clinical trials / Disease details
Clinical trials : 3 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000020543 | 2015/03/01 | 13/01/2016 | Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis | Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis - Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis | pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis | Oral administration of imatinib | National Hospital Organization Okayama Medical Center | NULL | Complete: follow-up complete | 18years-old | Not applicable | Male and Female | 8 | Not applicable | Japan |
| 2 | NCT00891527 (ClinicalTrials.gov) | October 2008 | 30/4/2009 | Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis | Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis | Pulmonary Veno Occlusive Disease | Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) | Boston Children's Hospital | NULL | Completed | N/A | N/A | All | 50 | Phase 1/Phase 2 | United States |